1. Home
  2. PLXS vs SYRE Comparison

PLXS vs SYRE Comparison

Compare PLXS & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Plexus Corp.

PLXS

Plexus Corp.

HOLD

Current Price

$239.19

Market Cap

7.2B

Sector

Technology

ML Signal

HOLD

Logo Spyre Therapeutics Inc.

SYRE

Spyre Therapeutics Inc.

HOLD

Current Price

$107.33

Market Cap

8.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLXS
SYRE
Founded
1979
2013
Country
United States
United States
Employees
20000
N/A
Industry
Electrical Products
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.2B
8.5B
IPO Year
1995
2015

Fundamental Metrics

Financial Performance
Metric
PLXS
SYRE
Price
$239.19
$107.33
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
12
Target Price
$206.50
$85.08
AVG Volume (30 Days)
292.7K
794.3K
Earning Date
04-29-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
56.11
N/A
EPS
4.90
N/A
Revenue
N/A
N/A
Revenue This Year
$14.31
N/A
Revenue Next Year
$8.29
N/A
P/E Ratio
$48.49
N/A
Revenue Growth
N/A
N/A
52 Week Low
$132.03
$14.51
52 Week High
$307.06
$110.18

Technical Indicators

Market Signals
Indicator
PLXS
SYRE
Relative Strength Index (RSI) 40.90 60.88
Support Level $233.67 $93.45
Resistance Level $299.61 N/A
Average True Range (ATR) 10.37 4.53
MACD -2.64 -0.09
Stochastic Oscillator 16.71 87.74

Price Performance

Historical Comparison
PLXS
SYRE

About PLXS Plexus Corp.

Plexus Corp designs, manufactures, and services complex products in demanding regulatory environments, supporting life-saving medical devices, mission-critical aerospace and defense products, industrial automation systems, and semiconductor capital equipment. Its integrated lifecycle solutions span design and development, supply chain solutions, new product introduction, manufacturing, and sustaining services for market and disruptive companies in the Aerospace/Defense, Healthcare/Life Sciences, and Industrial sectors. The Company operates through three reportable segments: AMER, APAC, and EMEA, with the majority of revenue from the APAC segment.

About SYRE Spyre Therapeutics Inc.

Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

Share on Social Networks: